Inspection Record

Triad Isotopes Inc. — FDA 483 Findings

US FDAInspected 2015-07-23Published 2024-01-17 4 findingsTraining and personnelQuality unit oversightAseptic processing and sterility assuranceLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Training and personnel

Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug products is not appropriate for t he duties they perform.

2Quality unit oversight

The responsibilities aod procedures applicable to the quality contro l unit are not in writing and fully followed.

3Aseptic processing and sterility assurance

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to asep tic processing of drug products.

4Laboratory and QC controls

Laboratory controls do n ot include the establishment of scientifically sound and appropriate test procedures designed to ass ure that drug products conform tO appropriate standards of identity, strength, quality and purity.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Triad Isotopes Inc. company profile — full history US FDA documents, 2024 Go to Findings search